Unicycive Therapeutics Shareholders Urged to Join Class Action Lawsuit

In light of recent developments, it is essential for shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) who have incurred financial losses to reach out to The Gross Law Firm. This firm has stepped forward to announce that it is handling a pending class action lawsuit aimed at advocating for affected investors.

Understanding the Allegations

The accusations surrounding Unicycive Therapeutics revolve around significant discrepancies in the company’s public statements regarding its readiness to comply with FDA manufacturing regulations. Specifically, the claims suggest that the company’s assertions were overly optimistic, leading investors to believe in a stronger regulatory approval process for their oxylanthanum carbonate new drug application than was actually the case. This misrepresentation has sparked concerns among shareholders who feel that they were misled during the class period, which spans from March 29, 2024, to June 27, 2025.

Join the Class Action

Shareholders who purchased UNCY shares within the specified timeframe are invited to participate in the class action. Potential participants are encouraged to register quickly, especially since the deadline to seek lead plaintiff status is set for October 14, 2025. Being appointed as a lead plaintiff is not a requirement to join the recovery efforts, which should ease the process for involved shareholders. More details about registration can be found on The Gross Law Firm's website, where interested parties can also submit their information easily.

The Role of The Gross Law Firm

The Gross Law Firm is a highly regarded establishment in the field of class action lawsuits, specializing in protecting investors' rights. Their mission revolves around safeguarding individuals who have experienced losses due to deceitful practices or fraud by corporations. Investors who engage with the firm will not only have access to updates on the progression of the case but will also benefit from monitoring tools that keep them informed regarding their claims.

Why You Should Act Now

It is imperative for shareholders to act swiftly. The legal intricacies involved in class action lawsuits necessitate participants to engage promptly and meticulously, ensuring that they stay informed regarding their rights and potential recovery avenues. By registering, shareholders will be part of a larger collective working to hold Unicycive accountable for the alleged misinformation and protect their financial interests.

In conclusion, if you are a shareholder of Unicycive Therapeutics, now is the time to act. Reach out to The Gross Law Firm to understand your rights and explore options for compensation effectively. The firm emphasizes that joining this case does not entail any financial obligation upfront, making it an accessible route for all affected investors.

For more information or to register for the class action, you can contact The Gross Law Firm at:

- Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
- Phone: (646) 453-8903
- Email: [email protected]

By taking these crucial steps, shareholders can safeguard their interests and contribute to a collective effort in holding corporations accountable for their actions.